[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo (Q33194892)

23 July 2017

title

[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo (English)

1 reference

23 July 2017

Simon A Hinke

1

1 reference

23 July 2017

Susanne Manhart

2

1 reference

23 July 2017

Kerstin Kühn-Wache

3

1 reference

23 July 2017

Cuilan Nian

4

1 reference

23 July 2017

Hans-Ulrich Demuth

5

1 reference

23 July 2017

Raymond A Pederson

6

1 reference

23 July 2017

Christopher H S McIntosh

7

1 reference

23 July 2017

language of work or name

English

0 references

publication date

10 November 2003

1 reference

Journal of Biological Chemistry

23 July 2017

published in

1 reference

23 July 2017

volume

279

1 reference

23 July 2017

issue

6

1 reference

23 July 2017

page(s)

3998-4006

1 reference

New developments in the incretin concept

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

The glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Gastric inhibitory polypeptide: the neglected incretin revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M311304200

21 January 2018

Identifiers

DOI

10.1074/JBC.M311304200

1 reference

23 July 2017

1 reference